UTv Videos

Pedro C. Barata, MD, MSc, FACP, discusses preliminary findings from the phase 3 ProstACT Global study evaluating 177Lu-rosopatamab plus standard-of-care for patients with mCRPC.

Tanya B. Dorff, MD, FASCO, shares phase 1 data on ABBV-969, an investigational antibody-drug conjugate being explored for metastatic castration-resistant prostate cancer.

Kim Chi, MD, highlights findings from a pre-planned analysis of the PLUDO trial examining the impact of crossover on survival outcomes between 177Lu-PSMA-617 vs docetaxel in mCRPC.

Lucia Nappi, MD, PhD, FRCPC, highlights key findings from an interim analysis of SWOG S1823, evaluating miR371 for predicting active germ cell malignancy in patients with early-stage testicular cancer.

Alicia K. Morgans, MD, MPH, discusses key findings from the ARACOG study, assessing cognitive outcomes between patients who received darolutamide vs those who received enzalutamide for advanced prostate cancer.

Rana R. McKay, MD, FASCO, highlights phase 2 data on radium-223 dichloride plus cabozantinib for patients with renal cell carcinoma with bone metastases.

Mark Fleming, MD, and Manoj Bupathi, MD, MS, highlight the key studies and sessions in GU oncology that they're most anticipating at ASCO 2026.

Objective performance indicators in robotic surgery are providing the first quantitative framework for evaluating surgical technique, according to Michael Stifelman, MD, professor and chair of urology at Hackensack Meridian Health, whose early prostatectomy data link specific intraoperative metrics to functional outcomes—while governance frameworks, cultural adoption, and the prospect of real-time intraoperative guidance define the near-term challenges and long-term trajectory.

Break Wave lithotripsy met all pivotal non-inferiority end points vs shock wave lithotripsy.

Keith Xavier, MD, URPS, highlights data from the TITAN 2 study looking at the impact of site of service on outcomes with the Medtronic implantable tibial neuromodulation system.

Archan Khandekar, MD, highlights key findings from a study evaluating LLM architectures for answering patient-facing urologic questions.

Mark D. Tyson II, MD, MPH, discusses findings from the phse 3b PATAPSCO study, evaluating durvalumab plus BCG for patients with BCG-naïve, high-risk NMIBC.

Mark Garzotto, MD, discusses phase 3 data on aglatimagene besadenovec plus standard-of-care external beam radiation therapy with or without short-course androgen deprivation therapy in localized prostate cancer.

Bashir Al Hussein Al Awamlh, MD, MPH, discusses findings from an international registry study evaluating how baseline sexual interest may influence sexual bother outcomes after treatment for localized prostate cancer.

Sarah P. Psutka, MD, MSc, reflects on her AUA 2026 talk regarding frailty and surgical outcomes in urologic oncology.

Rana R. McKay, MD, FASCO, shares results from the ARASEC study, which evaluated darolutamide plus ADT in mHSPC using a novel external control-arm design.

In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.

The phase 1/2 ResQ133A-NMIBC trial (NCT06800963) is evaluating intravesical recombinant BCG in patients with BCG-naïve high-risk NMIBC across US sites, with safety as the primary end point and complete response and disease-free survival as secondary end points, building on European data showing 50% response rates and no dose-limiting toxicities in BCG-unresponsive disease.

Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC.

The INTIBIA Pivotal Study—the first sham-controlled, double-blind RCT of an implantable tibial nerve stimulation device—demonstrated significantly greater clinically meaningful improvements in symptom bother, health-related quality of life, and patient global impression at 3 months compared with sham, with durable benefits through 12 months.

Chad A. Reichard, MD, highlights real-world data presented at AUA 2026 on re-induction with nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

ARASEC provides US-based, contemporary evidence supporting darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, demonstrating a 71% reduction in prostate cancer-specific mortality compared with a historical ADT control—while its use of propensity score matching with an external phase 3 control arm represents a novel trial design that may inform future studies in rapidly evolving treatment landscapes.

Health services research at UNC is informing community-based outreach efforts in prostate cancer—including engagement with HBCUs and patient groups across North Carolina—by centering patient and community perspectives to identify and address the barriers that prevent evidence-based care from reaching those who need it most.

A real-world analysis found that PSADT was undocumented in most patients with high-risk biochemical recurrence of prostate cancer, potentially delaying treatment initiation and underestimating progression risk.

Krishnan discusses how prolapse stage, patient lifestyle, and nuanced mesh counseling inform individualized decision-making around robotic sacrocolpopexy vs vaginal reconstructive repair.

The 2026 AUA Annual Meeting will feature significant bladder cancer data, a plenary lecture on screening and overdetection, and programming that integrates advanced practice providers across sessions, against a backdrop of AUA-driven policy wins including removal of the vaginal estrogen black box warning and early steps toward a federal Office of Men's Health.

Isaac Y. Kim, MD, PhD, MBA, reflects on concerning trends in prostate cancer mortality, emphasizing how advances in diagnostics, treatment, and artificial intelligence may improve outcomes in the future.

Yeonsoo Sara Lee, MD, highlights the key networking and education opportunities she's most looking forward to at AUA 2026.